(TheNewswire)
LONDON, ONTARIO - TheNewswire - October 29, 2020 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company,was invited by the TMX Group to present today at the first-ever TSXLife Sciences Investor Day hosted by the Toronto Stock Exchange andthe TSX Venture Exchange. Dr. Philip Toleikis, President and CEO,provided a virtual investor presentation to attendees.
Alternately, t h is video presentation is now availableat www.sernova.com
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicinetherapeutic solutions using a medical device (Cell Pouch(TM)) andimmune protected therapeutic cells/tissues (i.e. human donor cells,corrected human cells, and stem cell-derived cells) to improve thetreatment and quality of life of people with chronic metabolicdiseases such as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through cellular production ofproteins or hormones missing or in short supply within the body. Formore information, please visit www.sernova.com .
ABOUT SERNOVA'S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro-encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device, upon implantation, is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins, hormones, or other factors as required to treatdisease. Sernova is currently conducting a Phase I/II study at theUniversity of Chicago and has demonstrated encouraging early safetyand efficacy indicators. The Cell Pouch, in combination withtherapeutic cells/tissues, has been shown to provide long-term safetyand efficacy in preclinical models of diabetes, hemophilia A and otherindications supporting our therapeutics platform.
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Forward-Looking Information
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute"forward-looking statements" that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of theCompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflectmanagement's beliefs with respect to future events and are based oninformation currently available to management on the date suchstatements were made. Many factors could cause Sernova's actualresults, performances or achievements to not be as anticipated,estimated or intended or to differ materially from those expressed orimplied by the forward-looking statements contained in this newsrelease. Such factors could include, but are not limited to, theCompany's ability to secure additional financing and licensingarrangements on reasonable terms, or at all; ability to conduct allrequired preclinical and clinical studies for the Company's Cell PouchSystem and/or related technologies, including the timing and resultsof those trials; ability to obtain all necessary regulatory approvals,or on a timely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the Company's quarterly and annual filings available onwww.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2020 TheNewswire - All rights reserved.